PRNewsWire
20 Jun 2026, 02:00 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
ADMA Biologics is facing a class action securities lawsuit alleging the company used 'channel stuffing' to artificially inflate revenue. — Allegations of revenue manipulation through channel stuffing are severe and typically lead to a loss of investor trust and potential valuation write-downs.
-0.80The lawsuit claims ADMA Biologics failed to disclose material information regarding an undisclosed related party transaction. — Undisclosed related party transactions suggest poor corporate governance and potential conflicts of interest.
-0.50ADMA Biologics is accused of lacking adequate internal controls over its business operations and reporting. — Weak internal controls increase the risk of future financial misstatements and regulatory penalties.
-0.40Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company is mentioned in the context of a securities fraud class action following weak revenue guidance and a significant stock decline.
The company is facing a class action lawsuit alleging securities fraud, channel stuffing, and lack of internal controls.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
4h ago
